stockrow
Saturday 7 November 2026
Export DSGN’s income statement to Excel — free account
Design Therapeutics, Inc.
DSGN Healthcare Biotechnology
- EPS
- −7.27%
- Free cash flow
- −7.00%
Quarter to September 2026, against a year earlier
10.19
0.52
+5.38%
Follow DSGN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | — | — | — | — | — | 0 | — | 5 | 5 | 5 | 0.0% | |
| Gross margin, % | — | — | — | — | 100.00 | 0.00 | 0.00 | — | — | — | 0.00 | (100.0) pt | ||||||
| EBT | — | — | — | (2) | (8) | (36) | (63) | (67) | (50) | (70) | (74) | +80.1% | ||||||
| EBT margin, % | — | — | — | 0.00 | (3,663.72) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (2) | (8) | (36) | (63) | (67) | (50) | (70) | (74) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.04) | (0.52) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) | (1.20) | +76.8% | ||||||
| Cash flow | — | — | — | 0.00 | (0.55) | (0.64) | (0.92) | (1.05) | (0.76) | (0.95) | (0.94) | +169.0% | ||||||
| Capex | — | — | — | 0.00 | 0.00 | (0.03) | (0.02) | 0.00 | (0.01) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | 0.00 | (0.55) | (0.67) | (0.94) | (1.05) | (0.77) | (0.95) | (0.94) | +169.2% | ||||||
| Book value | — | — | — | (0.07) | (0.72) | 8.32 | 5.88 | 4.96 | 4.28 | 3.71 | 3.21 | n/m | ||||||
| Shares, m | — | — | — | 56 | 16 | 46 | 56 | 56 | 57 | 57 | 61 | +0.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | — | — | — | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | 2,900.08 | — | — | — | — | — | 2,842.20 | — | ||||||
| P/B | — | — | — | — | 0.00 | — | — | — | — | — | 3.18 | — | ||||||
| EV/Sales | — | — | — | — | 2,740.38 | — | — | — | — | — | 1,919.15 | — | ||||||
| EV/FCF | — | — | — | — | (71.44) | — | — | — | — | — | (7.31) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | 0 | (9) | (29) | (51) | (59) | (43) | (54) | (59) | +170.4% | |||||
| Capex | — | — | — | — | 0 | (2) | (1) | 0 | 0 | 0 | 0 | +20.5% | ||||||
| Free cash flow | — | — | — | 0 | (9) | (31) | (52) | (59) | (43) | (55) | (59) | +170.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | (4) | 34 | 380 | 324 | 275 | 240 | 211 | 201 | n/m | |||||
| Net debt | — | — | — | 1 | (36) | (384) | (330) | (282) | (245) | (220) | (209) | n/m | ||||||
| Shareholders’ equity | — | — | — | (4) | (11) | 382 | 327 | 278 | 242 | 213 | 202 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (4,548.89) | (45.24) | (16.64) | (17.30) | (21.20) | (18.31) | (29.18) | (34.57) | +4,519.7 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 27.37 | 110.72 | (19.16) | (17.85) | (22.10) | (19.08) | (30.70) | (36.87) | (58.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 20 | 38 | 58 | 58 | 54 | 54 | — | +22.0% | |||||
| Revenue/emp, $m | — | — | — | — | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2020 · latest quarter Dec 2020 · fundamentals updated 6 Nov 2026
Design Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DBVT DBV Technologies S.A. | $615.8M | — (loss-making) | — | −42.86% (below 0%: shrinking) | n/m | −64.93% (below 0%: shrinking) | 100.00% | (4,043.75%) | Compare |
| CADL Candel Therapeutics, Inc. | $615.2M | — (loss-making) | — (loss-making) | 0.00% | n/m | −93.35% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| HELP Cybin Inc. | $613.0M | — (loss-making) | — (loss-making) | — | n/m | −25.60% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GERN Geron Corporation | $610.4M | — (loss-making) | — (loss-making) | +27.45% (above 0%: growing) | n/m | +176.13% (above 0%: growing) | 89.95% | 9.63% | Compare |
| DSGN Design Therapeutics, Inc. | $605.2M | — (loss-making) | — (loss-making) | — | n/m | −7.00% (below 0%: shrinking) | 0.00% | 0.00% | |
| KURA Kura Oncology, Inc. | $604.9M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | Compare |
| AVBP ArriVent BioPharma, Inc. | $603.0M | — (loss-making) | — | — | n/m | −51.51% (below 0%: shrinking) | — | 0.00% | Compare |
| IMMX Immix Biopharma, Inc. | $596.9M | — (loss-making) | — | — | n/m | −116.22% (below 0%: shrinking) | — | 0.00% | Compare |
| OBX Obsidian Therapeutics, Inc | $593.0M | — | — | — | n/m | — | — | 0.00% | Compare |
| Median of peers | $607.7M | — | — | +13.73% | — | −64.93% | 89.95% | 0.00% |
Pay and ownership Proxy statement filed 23 April 2026
Ownership
Directors and executive officers, together
17.10%
Aseem Z. Ansari, Ph.D.
12.40%
Simeon George, M.D.
10.60%
SR One Capital Fund I Aggregator, LP
10.50%
Point72 Asset Management, L.P.
8.60%
Light Irrevocable Trust #1 dated April
6.10%
Star Irrevocable Trust #1 dated April
6.10%
Quan Venture Fund II, L.P.
5.40%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement